David M Hughes1, Sarah Berhane1, C A Emily de Groot2, Hidenori Toyoda3, Toshifumi Tada3, Takashi Kumada4, Shinji Satomura5, Naoshi Nishida6, Masatoshi Kudo6, Toru Kimura7, Yukio Osaki8, Ruwanthi Kolamunage-Dona1, Ruben Amoros9, Tom Bird10, Marta Garcίa-Fiñana1, Philip Johnson11. 1. Department of Biostatistics. 2. Department of Economics, University of St Andrews, St Andrews, United Kingdom. 3. Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan. 4. Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan. 5. Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan. 6. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. 7. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan. 8. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan; Department of Internal Medicine, Meiwa Hospital, Nishinomiya, Japan. 9. School of Mathematics. 10. Medical Research Council Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. 11. Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. Electronic address: Philip.Johnson@liverpool.ac.uk.
Abstract
BACKGROUND & AIMS: Ultrasound (US)-based screening has been recommended for patients with an increased risk of hepatocellular carcinoma (HCC). US analysis, however, is limited in patients who are obese or have small tumors. The addition of serum level of α-fetoprotein (AFP) measurements to US analysis can increase detection of HCC. We analyzed data from patients with chronic liver disease, collected over 15 years in an HCC surveillance program, to develop a model to assess risk of HCC. METHODS: We collected data from 3450 patients with chronic liver disease undergoing US surveillance in Japan from March 1998 through April 2014, and followed them up for a median of 8.83 years. We performed longitudinal discriminant analysis of serial AFP measurements (median number of observations/patient, 56; approximately every 3 months) to develop a model to determine the risk of HCC. We validated the model using data from 2 cohorts of patients with chronic liver disease in Japan (404 and 2754 patients) and 1 cohort in Scotland (1596 patients). RESULTS: HCC was detected in 413 patients (median tumor diameter, 1.8 cm), during a median follow-up time of 6.60 years. In the development data set, the model identified patients who developed HCC with an area under the curve of 0.78; it correctly identified 74.3% of patients who did develop HCC, and 72.9% of patients who did not. Overall, 73.1% of patients were classified correctly. The model could be used to assign patients to a high-risk group (27.5 HCCs/1000 patient-years) vs a low-risk group (4.9 HCCs/1000 patient-years). A similar performance was observed when the model was used to assess patients with cirrhosis. Analysis of the validation cohorts produced similar results. CONCLUSIONS: We developed and validated a model to identify patients with chronic liver disease who are at risk for HCC based on change in serum AFP level over time. The model could be used to assign patients to high-risk vs low-risk groups, and might be used to select patients for surveillance.
BACKGROUND & AIMS: Ultrasound (US)-based screening has been recommended for patients with an increased risk of hepatocellular carcinoma (HCC). US analysis, however, is limited in patients who are obese or have small tumors. The addition of serum level of α-fetoprotein (AFP) measurements to US analysis can increase detection of HCC. We analyzed data from patients with chronic liver disease, collected over 15 years in an HCC surveillance program, to develop a model to assess risk of HCC. METHODS: We collected data from 3450 patients with chronic liver disease undergoing US surveillance in Japan from March 1998 through April 2014, and followed them up for a median of 8.83 years. We performed longitudinal discriminant analysis of serial AFP measurements (median number of observations/patient, 56; approximately every 3 months) to develop a model to determine the risk of HCC. We validated the model using data from 2 cohorts of patients with chronic liver disease in Japan (404 and 2754 patients) and 1 cohort in Scotland (1596 patients). RESULTS: HCC was detected in 413 patients (median tumor diameter, 1.8 cm), during a median follow-up time of 6.60 years. In the development data set, the model identified patients who developed HCC with an area under the curve of 0.78; it correctly identified 74.3% of patients who did develop HCC, and 72.9% of patients who did not. Overall, 73.1% of patients were classified correctly. The model could be used to assign patients to a high-risk group (27.5 HCCs/1000 patient-years) vs a low-risk group (4.9 HCCs/1000 patient-years). A similar performance was observed when the model was used to assess patients with cirrhosis. Analysis of the validation cohorts produced similar results. CONCLUSIONS: We developed and validated a model to identify patients with chronic liver disease who are at risk for HCC based on change in serum AFP level over time. The model could be used to assign patients to high-risk vs low-risk groups, and might be used to select patients for surveillance.
Authors: Devan Kansagara; Joel Papak; Amirala S Pasha; Maya O'Neil; Michele Freeman; Rose Relevo; Ana Quiñones; Makalapua Motu'apuaka; Janice H Jou Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson Journal: Gastroenterology Date: 2014-01-23 Impact factor: 22.682
Authors: Ju Dong Yang; Benyam D Addissie; Kristin C Mara; William S Harmsen; Jianliang Dai; Ning Zhang; Nicha Wongjarupong; Hawa M Ali; Hamdi A Ali; Fatima A Hassan; Sravanthi Lavu; Jessica L Cvinar; Nasra H Giama; Catherine D Moser; Katsuyuki Miyabe; Loretta K Allotey; Alicia Algeciras-Schimnich; J Paul Theobald; Melissa M Ward; Mindie H Nguyen; Alex S Befeler; K Rajender Reddy; Myron Schwartz; Denise M Harnois; Hiroyuki Yamada; Sudhir Srivastava; Jo Ann Rinaudo; Gregory J Gores; Ziding Feng; Jorge A Marrero; Lewis R Roberts Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-21 Impact factor: 4.090
Authors: Thomas G Bird; Polyxeni Dimitropoulou; Rebecca M Turner; Sara J Jenks; Pearce Cusack; Shiying Hey; Andrew Blunsum; Sarah Kelly; Catharine Sturgeon; Peter C Hayes; Sheila M Bird Journal: PLoS One Date: 2016-06-16 Impact factor: 3.240